Calocurb triples revenue, raises $27m as it rides the GLP-1 boom

Chris KeallTechnology Editor/Senior Business Writer·NZ Herald·8 Sep, 2026 07:00 PM6 mins to read‌Calocurb CEO Sarah Kennedy discusses the company's ambitions to scale its plant-based weight-loss product in a market dominated by pharmaceutical giants.Calocurb, the Auckland maker of a diet-suppressing supplement, has raised $27 million in a Series A venture capital round as it continues to piggyback on the rise-and-rise of GLP-1 weight-loss drugs like Ozempic and Wegovy. Founder and chief executive Sarah Kennedy says the raise, which follows seed rounds that have